Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring ...

The correction is one of the largest in Abbott's recent continuous glucose monitor business, which dominates the global ...

Abbott just announced a “medical device correction” for approximately three million glucose sensor monitors in the U.S., ...

Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may ...

Abbott (NYSE:ABT) announced today that it issued a device correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors ...

Companies in that second group are the ones that income investors should aim to keep in their portfolios for good. Two dividend stocks that fit this profile are Abbott Laboratories (NYSE: ABT) and ...

These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM ...

The global Blood Glucose Monitoring System Market, valued at US$15.16 billion in 2024, stood at US$16.46 billion in 2025 and ...

Global Insulin Delivery Device Market Growth Overview The global insulin delivery device market is poised to expand at a CAGR of around 8% during the forecast period, driven by the increasing global ...

The global Blood Glucose Monitoring System Market, valued at US$15.16 billion in 2024, stood at US$16.46 billion in 2025 and is projected to ...

Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system.

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...